Cost–Utility Analysis of Pharmacogenetic Testing Based on CYP2C19 or CYP2D6 in Major Depressive Disorder: Assessing the Drivers of Different Cost-Effectiveness Levels from an Italian Societal Perspective.
Saved in:
| Title: | Cost–Utility Analysis of Pharmacogenetic Testing Based on CYP2C19 or CYP2D6 in Major Depressive Disorder: Assessing the Drivers of Different Cost-Effectiveness Levels from an Italian Societal Perspective. |
|---|---|
| Authors: | Carta, Andrea1 (AUTHOR), Del Zompo, Maria2 (AUTHOR), Meloni, Anna2 (AUTHOR), Mola, Francesco1 (AUTHOR), Paribello, Pasquale3,4 (AUTHOR), Pinna, Federica3,4 (AUTHOR), Pinna, Marco3 (AUTHOR), Pisanu, Claudia2 (AUTHOR), Manchia, Mirko3,4,5 (AUTHOR), Squassina, Alessio2 (AUTHOR), Carpiniello, Bernardo3,4 (AUTHOR), Conversano, Claudio1 (AUTHOR) conversa@unica.it |
| Source: | Clinical Drug Investigation. Sep2022, Vol. 42 Issue 9, p733-746. |
| Database: | SPORTDiscus with Full Text |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
